Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Carbonic Anhydrase III Polyclonal Antibody
Goat Polyclonal Antibody
Supplier: Invitrogen™ PA547265
Description
In direct ELISAs, approximately 5% cross-reactivity with recombinant human (rh) CA1, rhCA2, rhCA4, rhCA9, rhCA10, rhCA13 and rhCA14 is observed. Reconstitute at 0.2 mg/mL in sterile PBS.
Carbonic anhydrase III (CAIII) is a member of a multigene family (at least six separate genes are known) that encodes carbonic anhydrase isozymes. These carbonic anhydrases are a class of metalloenzymes that catalyze the reversible hydration of carbon dioxide and are differentially expressed in a number of cell types. The expression of the CA3 gene is strictly tissue specific and present at high levels in skeletal muscle and much lower levels in cardiac and smooth muscle. A proportion of carriers of Duchenne muscle dystrophy have a higher CA3 level than normal. The gene spans 10. 3 kb and contains seven exons and six introns.
Specifications
Carbonic Anhydrase III | |
Polyclonal | |
Unconjugated | |
Ca3 | |
BB219044; CA III; Ca3; CAH3; CAIII; CA-III; CAIII (Muscle); Car3; Car-3; Carbonate dehydratase III; carbonic anhydrase 3; Carbonic anhydrase III; carbonic anhydrase III, muscle specific; carbonic anhydrase-like protein; EC 4.2.1.1; epididymis secretory sperm binding protein Li 167mP; HEL-S-167mP | |
Goat | |
Antigen affinity chromatography | |
RUO | |
12350, 54232, 761 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Lyophilized |
Immunoprecipitation, Western Blot | |
0.2 mg/mL | |
PBS with 5% trehalose and No Preservative | |
P07451, P14141, P16015 | |
Ca3, Car3 | |
E. coli-derived recombinant human Carbonic Anhydrase III/CA3 Ala2-Lys260. | |
100 μg | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction